Navigation Links
Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
Date:9/6/2011

THE WOODLANDS, Texas, Sept. 6, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the Morgan Stanley Global Healthcare Conference in New York City on Wednesday, September 14, 2011 at 9:10 a.m. Eastern Time.  Dr. Sands will provide an overview on Lexicon's clinical development programs and milestones.

A live webcast of the event may be accessed on Lexicon's corporate website at www.lexpharma.com.  An archived version of the webcast will be available for 30 days after the event on the company's website.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
2. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
3. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
4. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
5. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
6. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
7. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
8. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
9. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
10. Lexicon to Provide First Quarter 2011 Financial Results
11. Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2017)...  NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology company ... demonstrating positive biochemical outcomes related to more frequent hemodialysis ... will be presented at the ERA-EDTA Congress being held ... . The research was conducted by ... Europe (KIHDNEy) Cohort team ...
(Date:5/30/2017)... TEL AVIV, Israel , May 30, 2017 /PRNewswire/ ... clinical stage pharmaceutical Company specializing in the development ... management will present a company overview at three ... The 7th Annual LD Micro Invitational: ... Date:                     ...
(Date:5/24/2017)... 2017  ivWatch LLC today announced the launch ... to enable seamless integration of ivWatch,s groundbreaking IV ... pumps and other devices. By integrating ivWatch technology ... help health care customers deliver a higher level ... IV therapy. "The ivWatch OEM Board ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own ... others prefer to read it, and some people don't like it at all. FindaTopDoc ... what they found: , Erotic literature can give readers a taste of their deepest, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ensuring meat products have ... highlight the importance of correctly using a meat thermometer. The videos feature University ... research on consumer food safety habits. Dr. Bruhn explains the variety of meat ...
(Date:6/23/2017)... West Palm Beach, FL (PRWEB) , ... June 23, 2017 , ... ... June 19, in Pinecrest, Florida. This is MD Now’s 28th facility overall and marks ... 12301 S. Dixie Highway, located one mile North of The Falls shopping mall. The ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... American Farmer, ... winning series, which is slated to air fourth quarter 2017. American Farmer airs Tuesdays ... Hansen, a Danish pharmacist, founded Chr. Hansen in Denmark in 1874 after a ...
(Date:6/23/2017)... ... 23, 2017 , ... Jusino Insurance Services, a locally owned ... greater Chicago metropolitan area, is embarking on a charity drive in conjunction with ... Founded in 1897, Hephzibah Children’s Association is one of the oldest social services ...
Breaking Medicine News(10 mins):